Advertisement

Head and Neck Malignancies: Chemotherapy and Radiation Perspective

  • Mohan Suntharalingam
  • Kathleen Settle
  • Kevin J. Cullen

Abstract

Squamous cell carcinomas of the head and neck represent approximately 5% of cancers diagnosed in the United States each year. More than 40,000 patients will be diagnosed this year, and worldwide this number will exceed 500,000 [1]. Although patients presenting with early-stage disease have high cure rates with either radiation therapy or surgery alone, those diagnosed with locally advanced disease have historically had poorer prognoses and limited therapeutic options. Although most of these cancers tend to remain clinically limited to the head and neck region, locally advanced tumors can still present a significant therapeutic challenge. These tumors are often characterized by invasion into surrounding anatomic structures such as muscle, bone, nerves, or blood vessels and often present with clinically detectable lymph node metastases. Surgical resection with adjuvant radiotherapy does offer a chance of cure for a portion of these patients; however, the opportunity for cure has come at a significant cost in terms of function and cosmesis [2], [3]. These patients have historically had poor long-term survival, and a significant portion die as a result of locoregional disease progression.

Keywords

Local Control Neck Cancer Radiat Oncol Biol Phys Radiation Therapy Oncology Group Locoregional Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937–1944.CrossRefPubMedGoogle Scholar
  3. 3.
    Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945–1952.CrossRefPubMedGoogle Scholar
  4. 4.
    Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92–98.CrossRefPubMedGoogle Scholar
  5. 5.
    Calais G, Le Floch O. [Concomitant radiotherapy and chemotherapy in the treatment of cancers of the upper respiratory and digestive tracts]. Bull Cancer Radiother 1996; 83:321–329.PubMedGoogle Scholar
  6. 6.
    Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091–2098.CrossRefPubMedGoogle Scholar
  7. 7.
    Al-Sarraf M, Pajak TF, Marcial VA, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer 1987; 59:259–265.CrossRefPubMedGoogle Scholar
  8. 8.
    Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798–1804.CrossRefPubMedGoogle Scholar
  9. 9.
    Forstiere AA, Maor M, Weber R, et al. Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone: results of the Intergroup trial R91-11. Proceedings of ASCO. J Clin Oncol 2001; 20:2a.Google Scholar
  10. 10.
    Stell PM. Adjuvant xhemotherapy in head and neck cancer. Semin Radiat Oncol 1992; 2:195–205.CrossRefPubMedGoogle Scholar
  11. 11.
    Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACHNC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355:949–955.PubMedGoogle Scholar
  12. 12.
    Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71:83–91.PubMedGoogle Scholar
  13. 13.
    Bourhis J, Pignon JP. Meta-analyses in head and neck squamous cell carcinoma. What is the role of chemotherapy? Hematol Oncol Clin North Am 1999; 13:769–775.CrossRefGoogle Scholar
  14. 14.
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310–1317.PubMedGoogle Scholar
  15. 15.
    Lee N, Puri DR, Blanco AI, Chao KS. Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 2007; 29:387–400.CrossRefPubMedGoogle Scholar
  16. 16.
    Wolden SL, Chen WC, Pfister DG, et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64:57–62.PubMedGoogle Scholar
  17. 17.
    Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183–232.CrossRefPubMedGoogle Scholar
  18. 18.
    Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004; 58:959–965.PubMedGoogle Scholar
  19. 19.
    Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29:27–36.CrossRefPubMedGoogle Scholar
  20. 20.
    Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935–1940.PubMedGoogle Scholar
  21. 21.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567–578.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee N, Xia P, Fischbein NJ, et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 2003; 57:49–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Mendenhall WM, Million RR, Stringer SP, et al. Squamous cell carcinoma of the glottic larynx: a review emphasizing the University of Florida philosophy. South Med J 1999; 92:385–393.PubMedGoogle Scholar
  24. 24.
    Wang CC, Efird J, Nakfoor B, et al. Local control of T3 carcinomas after accelerated fractionation: a look at the “gap”. Int J Radiat Oncol Biol Phys 1996; 35:439–441.CrossRefPubMedGoogle Scholar
  25. 25.
    Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48:7–16.CrossRefPubMedGoogle Scholar
  26. 26.
    Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000; 18:1458–1464.PubMedGoogle Scholar
  27. 27.
    Ahn YC, Lee KC, Kim DY, et al. Fractionated stereotactic radiation therapy for extracranial head and neck tumors. Int J Radiat Oncol Biol Phys 2000; 48:501–505.PubMedGoogle Scholar
  28. 28.
    Cmelak AJ, Cox RS, Adler JR, et al. Radiosurgery for skull base malignancies and nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1997; 37:997–1003.PubMedGoogle Scholar
  29. 29.
    Spencer SA, Wheeler RH, Peters GE, et al. Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol 1999; 22:1–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001; 51:1299–1304.PubMedGoogle Scholar
  31. 31.
    Langer C, Damsker J, Ridge A. Reirradiation: exploring new territory in the therapy of recurrent head and neck cancer. Clin Adv Hematol Oncol 2003; 1:424–429, 440.PubMedGoogle Scholar
  32. 32.
    Horowitz E HJ, Langer C, Nicolaou N, et al. RTOG 99-11: Phase II study of concurrent chemotherapy and re-irradiation for patients with recurrent squamous cell cancer of the head and neck. Int J Biol Phys Radiat Oncol 2005; 63(Suppl):185.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Mohan Suntharalingam
    • 1
  • Kathleen Settle
    • 2
  • Kevin J. Cullen
    • 3
    • 4
  1. 1.Department of Radiation OncologyUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.Department of Radiation OncologyUniversity of Maryland Medical SystemsBaltimoreUSA
  3. 3.Greenebaum Cancer CenterUniversity of MarylandUSA
  4. 4.University of Maryland Medical CenterBaltimoreUSA

Personalised recommendations